華森製藥(002907.SZ):公司8個產品完成了境內生產藥品備案
格隆匯5月17日丨華森製藥(002907.SZ)公佈,公司於近日從國家藥監局網站陸續查詢獲知公司8個產品完成了境內生產藥品備案(包括4個產品生產地址變更申請、3個產品藥品有效期變更申請及1個產品説明書及標籤修訂申請),並於國家藥監局網站公示備案。
公司五期項目集成了MES、SCADA、DCS等系統,結合大數據、人工智能,並將進行cGMP認證。此次部分產品生產場地轉移至五期項目,有助於進一步提升相關產品質量及滿足市場供應。同時,部分產品有效期延長及修改説明書和標籤等,有利於公司提升產品市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.